Expertise in
10
conditions

Dr. Zeenat Safdar

Pulmonary Medicine
Tmh Physician Associates PLLC
6565 Fannin St, 
Houston, TX 
Accepting New Patients
Offers Telehealth
Expertise in
10
conditions
Tmh Physician Associates PLLC
6565 Fannin St, 
Houston, TX 

Overview

Zeenat Safdar is a Pulmonary Medicine provider in Houston, Texas. Dr. Safdar is highly rated in 10 conditions, according to our data. Her top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Pulmonary Fibrosis, Acute Interstitial Pneumonia, and Lung Transplant. Dr. Safdar is currently accepting new patients.

Her clinical research consists of co-authoring 52 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Pulmonary Medicine

Licenses

Internal Medicine in TX

Hospital Affiliations

Houston Methodist Hospital
Houston Methodist West Hospital
Houston Methodist Baytown Hospital
Houston Methodist Sugarland Hospital
Houston Methodist Willowbrook Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health
  • EPO
  • HMO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

TMH PHYSICIAN ASSOCIATES PLLC
6565 Fannin St, Houston, TX 77030
Other Locations
TMH PHYSICIAN ASSOCIATES PLLC
7575 San Felipe St, Suite 155, Houston, TX 77063
TMH PHYSICIAN ASSOCIATES PLLC
16605 Sw Fwy 410, Methodist Diag Card Of Hou, Sugar Land, TX 77479
TMH PHYSICIAN ASSOCIATES PLLC
4710 Bellaire Blvd, Bellaire, TX 77401
TMH PHYSICIAN ASSOCIATES PLLC
6445 Main St, Houston, TX 77030

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Ralinepag When Added to PAH Standard of Care or PAH Specific Background Therapy in Subjects With WHO Group 1 PAH
Enrollment Status: Completed
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drug: Ralinepag
Study Phase: Phase 3
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
An Extended Access Program to Assess Long-term Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Enrollment Status: Terminated
Publish Date: June 11, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
A Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmonary Arterial Hypertension
Enrollment Status: Terminated
Publish Date: June 04, 2025
Intervention Type: Drug
Study Phase: Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Biological
Study Drug: Sotatercept
Study Phase: Phase 3
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study to Compare the Efficacy and Safety of Sotatercept (ACE-011) Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)
Enrollment Status: Completed
Publish Date: April 19, 2023
Intervention Type: Drug, Other
Study Drug: Sotatercept
Study Phase: Phase 2
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) in Heart Failure With Preserved Ejection Fraction (HFpEF)
Enrollment Status: Terminated
Publish Date: November 10, 2020
Intervention Type: Drug
Study Phase: Phase 3
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
An Open-label Extension Study of Oral Treprostinil in Subjects With Pulmonary Hypertension (PH) Associated With Heart Failure With Preserved Ejection Fraction (HFpEF) - A Long-term Follow-up to Study TDE-HF-301
Enrollment Status: Terminated
Publish Date: October 22, 2020
Intervention Type: Drug
Study Phase: Phase 3
View 6 Less Clinical Trials

52 Total Publications

Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World Setting.
Incremental Burden of Pulmonary Hypertension Among Patients With Interstitial Lung Disease in the Real-World Setting.
Journal: Pulmonary circulation
Published: April 17, 2025
Similar Doctors
Expertise in
12
conditions
Dr. Sandeep Sahay
Pulmonary Medicine | Intensive Care Medicine
Expertise in
12
conditions
Dr. Sandeep Sahay
Pulmonary Medicine | Intensive Care Medicine

Tmh Physician Associates PLLC

7575 San Felipe St, Suite 155, 
Houston, TX 
 (6.7 miles away)
713-266-9955
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sandeep Sahay is a Pulmonary Medicine specialist and an Intensive Care Medicine provider in Houston, Texas. Dr. Sahay is highly rated in 12 conditions, according to our data. His top areas of expertise are Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, Acute Interstitial Pneumonia, Lung Transplant, and Embolectomy. Dr. Sahay is currently accepting new patients.

Nicola Hanania
Expertise in
8
conditions
Dr. Nicola Hanania
Pulmonary Medicine
Expertise in
8
conditions
Dr. Nicola Hanania
Pulmonary Medicine

Baylor Medicine Cystic Fibrosis

7200 Cambridge St, 
Houston, TX 
 (0.7 miles away)
713-798-2400
Languages Spoken:
English
See accepted insurances

Nicola Hanania is a Pulmonary Medicine provider in Houston, Texas. Dr. Hanania is highly rated in 8 conditions, according to our data. His top areas of expertise are Chronic Obstructive Pulmonary Disease (COPD), Asthma, Eosinophilic Asthma, and Emphysema.

Expertise in
7
conditions
Dr. Joseph Varon
Pulmonary Medicine
Expertise in
7
conditions
Dr. Joseph Varon
Pulmonary Medicine
2219 Dorrington St, 
Houston, TX 
 (0.8 miles away)
713-669-1670
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Joseph Varon is a Pulmonary Medicine provider in Houston, Texas. Dr. Varon is highly rated in 7 conditions, according to our data. His top areas of expertise are COVID-19, Chronic Obstructive Pulmonary Disease (COPD), Long Haul COVID, Lung Metastases, and Gastrostomy. Dr. Varon is currently accepting new patients.

Frequently Asked Questions about Dr. Zeenat Safdar

How do I make an appointment with Dr. Zeenat Safdar?

You can book an appointment with Dr. Zeenat Safdar by calling their office at 713-266-9955. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Zeenat Safdar a top-rated expert for Pulmonary Hypertension?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Zeenat Safdar is classified as an Elite expert for Pulmonary Hypertension, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Zeenat Safdar specialize in?

While Dr. Zeenat Safdar is a Pulmonary Medicine, they have specific expertise in Pulmonary Hypertension, Pulmonary Veno-Occlusive Disease, and Pulmonary Fibrosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pulmonary Medicine.

Does Dr. Zeenat Safdar participate in research or clinical trials?

Yes. Dr. Zeenat Safdar has published 52 articles and abstracts on conditions like Pulmonary Hypertension. You can view a list of Dr. Zeenat Safdar's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Zeenat Safdar accept my insurance?

Dr. Zeenat Safdar accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 713-266-9955 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Safdar's expertise for a condition
ConditionClose
View All 18 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile